NCT07647263

Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-03-24Est. Completion: 2029-06

Enrollment target: 124 participants

Locations

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Contact

Hao Zhoudlou515@163.com +8613862097709

Other microbiome trials you might be interested in

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerPhase 3Recruiting

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2-Negative Breast CarcinomaHormone Receptor-Positive Breast Carcinoma

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chem…

Birmingham, United StatesEst. completion May 31, 2032

View Trial →

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast CancerPhase 3Recruiting

Breast Ductal Carcinoma In SituInvasive Breast CarcinomaMulticentric Breast Carcinoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.